InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,224.80
(
0.09%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.58
(
0.66%
)
Bitcoin
62,657.36
(
-0.79%
)
Post# of 252311
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119895
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: WorstLuck post# 194470

Wednesday, 02/10/2016 12:46:20 PM

Wednesday, February 10, 2016 12:46:20 PM

Post# of 252311
(ENTA)—ABBV still hasn’t used its FDA priority review voucher purchased for $350M in Aug 2015 (#msg-116321586). IMO, it’s becoming more and more likely ABBV will use it for the ABT-493/ABT-530 pan-genotypic HCV regimen, which has six phase-3 trials in progress (#msg-119900756).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up